Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Epirubicin |
Synonyms | |
Therapy Description |
Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Epirubicin | Ellence | Epirubicin Hydrochloride | Chemotherapy - Anthracycline 13 | Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 P72R | breast cancer | unknown | Epirubicin | Phase I | Actionable | In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472). | 22903472 |